Related Experiment Video
Updated: Aug 14, 2025
Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
Published on: December 9, 2022
[WP1130 relieves septic shock in mice by inhibiting NLRP3 inflammasome activation]
1Department of Laboratory, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.
Objective:
To investigate the mechanism by which the small molecule compound WP1130 inhibits NLRP3 inflammasome activation and alleviates septic shock.
Methods:
Mouse bone marrow-derived macrophages (BMDM) and human THP-1 cells were pre-treated with WP1130 before stimulation with different NLRP3 inflammasome agonists (Nigericin, ATP, MSU and intracellular LPS transfection), and AIM2 inflammasomes were activated with poly A: T. The levels of caspase-1 and IL-1β in the cell culture supernatant were determined using Western blotting and ELISA, and mitochondrial damage in the cells was observed using confocal microscopy. In the animal experiment, male C57BL/6 mice were randomized into blank control group, septic shock group (LPS group) and WP1130 treatment group (WP1130+LPS group), and the levels of IL-1β and TNF-α in the serum and peritoneal cavity were detected using ELISA.
Results:
In murine BMDM and human THP-1 cells, WP1130 significantly inhibited NLRP3 agonists-induced caspase-1 and IL-1β secretion in a dose-dependent manner (P < 0.05) but did not obviously affect the secretion of such inflammatory factors as IL-6 and TNF-α that were not associated with inflammasomes (P>0.05). Treatment with WP1130 did not significantly affect poly A: T-induced activation of AIM2 inflammasomes (P>0.05) or induce obvious changes in mitochondrial damage, an upstream signal of NLRP3 inflammasome activation. In the mouse model of LPS-induced septic shock, WP1130 treatment significantly reduced the level of IL-1β (P < 0.05) without obviously affecting TNF-α level either in the serum or in the peritoneal cavity (P>0.05).
Conclusion:
WP1130 specifically inhibits NLRP3 inflammasome activation to alleviate LPS-induced septic shock in mice.
Insights
The small molecule WP1130 specifically inhibits NLRP3 inflammasome activation, reducing inflammatory markers and alleviating septic shock in mice. This targeted approach offers a potential therapeutic strategy for sepsis treatment.
Area of Science:
- Immunology and Molecular Biology: Investigating inflammasome pathways and their role in inflammatory diseases.
- Pharmacology: Exploring the therapeutic potential of small molecule inhibitors in critical conditions.
Context:
- Sepsis is a life-threatening condition characterized by a dysregulated host response to infection.
- The NLRP3 inflammasome plays a crucial role in initiating inflammatory responses during sepsis.
- Existing treatments for septic shock have limitations, necessitating the development of novel therapeutic agents.
Purpose:
- To elucidate the mechanism by which WP1130 inhibits NLRP3 inflammasome activation.
- To evaluate the efficacy of WP1130 in alleviating lipopolysaccharide (LPS)-induced septic shock in a mouse model.
Summary:
- WP1130 demonstrated dose-dependent inhibition of NLRP3 inflammasome activation, evidenced by reduced caspase-1 and IL-1β secretion in murine bone marrow-derived macrophages and human THP-1 cells.
- WP1130 did not affect AIM2 inflammasome activation or inflammatory markers not associated with inflammasomes, indicating specificity.
- In vivo, WP1130 treatment significantly reduced IL-1β levels in a mouse model of LPS-induced septic shock, without impacting TNF-α.
Impact:
- WP1130 specifically targets NLRP3 inflammasome activation, offering a potential therapeutic strategy for septic shock.
- The findings highlight WP1130 as a promising candidate for further preclinical and clinical development in sepsis treatment.
- Understanding the precise mechanism of WP1130 action could lead to the development of more effective anti-inflammatory therapies.
